All articles tagged with #polycythemia vera
In a 48-patient Phase 2 study for the rare blood cancer polycythemia vera, Silence Therapeutics' RNA drug divesiran achieved a clinical response in 88% of treated patients versus 19% on placebo, suggesting robust efficacy and potential competitiveness with Takeda's near-approval therapy.
Eli Lilly will acquire Ajax Therapeutics in a deal worth up to $2.3 billion to advance AJ1-11095, a first-in-class Type II JAK2 inhibitor in Phase 1 for myeloproliferative neoplasms, including myelofibrosis and polycythemia vera. Designed for deeper, more durable efficacy than current JAK2 inhibitors, AJ1-11095 aims to enable longer therapy duration and broader use across first- and second-line settings, with proof-of-concept data anticipated later in 2026 and registrational trials planned.